Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
October 15 2024
The journal Medicina recently reported the results of a double-blind and placebo-controlled pilot clinical trial evaluating the use of a micronutrient...
The journal Medicina recently reported the results of a double-blind and placebo-controlled pilot clinical trial evaluating the use of a micronutrient cocktail on parameters associated with liver fibrosis and steatosis among people with obesity and metabolic syndrome. One hundred ninety-six adults (median age 58) with obesity (BMI of 30 kg/m2 or higher, and an elevated abdominal circumference (AC)) and dyslipidemia were recruited, and randomized to receive either placebo or a daily dose of micronutrients, specifically 800 mcg 5-MTHF (5-methyltetrahydrofolate), 2g betaine, 1g ALA (alpha-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 500 mg choline bitartrate, 280 mg DHA (docosahexaenoic acid), and 1000 mcg vitamin B12.
One hundred fifty-five participants completed the 3-month trial which monitored changes in 6 outcomes, including BMI, AC, cholesterol and triglyceride levels, controlled attenuation parameter (CAP), and transient elastography (TE), the latter 2 outcomes assessed by FibroScan technology, providing a measure of liver fat content (steatosis) and liver stiffness (fibrosis), respectively. One significant limitation of this study was the low rate of FibroScan evaluation; while offered at baseline and at 3 months, only 39 participants received both scans.
Despite the low rate of FibroScan completion, those participants receiving micronutrient supplementation had a significant reduction in CAP compared to placebo, a decrease of 4% compared to an increase of 5.4%. A similar improvement in the percent change in TE was also observed, a significant drop of 7.8% with micronutrient supplementation vs. an 8.6% increase with placebo. No other significant changes were observed. While limited by size and completion rate, this study suggests that providing omega-3 fatty acids, methyl donors, and vitamin b12 may improve objective signs of metabolic dysfunction-associated steatotic liver disease (MASLD) in adults with obesity and metabolic syndrome.
Submit this form and you'll receive our latest news and updates.
As we celebrate the 4th of July, it’s the perfect time to enjoy the bounty of nutritious summer foods. A plethora of res...
Learn moreA systematic review and network analysis was recently published in PeerJ, evaluating the randomized clinical trials of v...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment